AR092555A1 - 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc - Google Patents

2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc

Info

Publication number
AR092555A1
AR092555A1 ARP130103279A ARP130103279A AR092555A1 AR 092555 A1 AR092555 A1 AR 092555A1 AR P130103279 A ARP130103279 A AR P130103279A AR P130103279 A ARP130103279 A AR P130103279A AR 092555 A1 AR092555 A1 AR 092555A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
cycloalkyl
halogen
pyridinyl
indoles
Prior art date
Application number
ARP130103279A
Other languages
English (en)
Inventor
Prinssen Eric
Riemer Claus
G Shankar Bavani
Stoll Theodor
Kolczewski Sabine
Limberg Anja
Malberg Jessica
Brunner Daniela
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47044777&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092555(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR092555A1 publication Critical patent/AR092555A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

2-oxo-2,3-dihidro-indoles de la fórmula general (1) en la que: el hexágono N¹ es fenilo o un grupo heteroarilo elegido entre piridinilo, pirimidinilo, imidazolilo, isoxazolilo y pirazolilo; el hexágono N² es fenilo o piridinilo, pero el átomo de N del grupo piridinilo puede ocupar cualquiera de las posiciones libres; R¹ es hidrógeno, alquilo inferior, alquilo inferior sustituido por halógeno, alcoxi inferior o halógeno; n es el número 1 ó 2; si n es el número 2, R¹ puede ser el mismo o no; R²/R² son con independencia entre sí alquilo inferior o junto con el átomo de carbono, al que están unidos, forman un anillo cicloalquilo C₃₋₆; R³ es alquilo inferior, cicloalquilo C₃₋₆, CH₂-cicloalquilo C₃₋₆, cicloalquilo C₃₋₆ en el que un átomo de carbono del anillo se ha reemplazado por -O-, (CH₂)₃-O-cicloalquilo C₃₋₆, alquilo inferior sustituido por hidroxi, alquilo inferior sustituido por halógeno, (CH₂)₃-S(O)₂-cicloalquilo C₃₋₆ o (CH₂)₂-S(O)₂-alquilo inferior; R⁴ es hidrógeno, halógeno o alquilo inferior; m es el número 1 ó 2; si m es el número 2, R⁴ puede ser igual o no; así como a sus sales farmacéuticamente aceptables, a una mezcla racémica, a sus enantiómeros correspondientes y/o isómeros ópticos y/o estereoisómeros. Estos compuestos son útiles en el tratamiento de enfermedades del SNC.
ARP130103279A 2012-09-13 2013-09-13 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc AR092555A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12184249 2012-09-13

Publications (1)

Publication Number Publication Date
AR092555A1 true AR092555A1 (es) 2015-04-22

Family

ID=47044777

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103279A AR092555A1 (es) 2012-09-13 2013-09-13 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc

Country Status (23)

Country Link
US (1) US9221816B2 (es)
EP (1) EP2895476B1 (es)
JP (1) JP6116693B2 (es)
KR (1) KR101706877B1 (es)
CN (1) CN104619701B (es)
AR (1) AR092555A1 (es)
AU (1) AU2013314417B2 (es)
BR (1) BR112015005186A2 (es)
CA (1) CA2883817C (es)
CL (1) CL2015000559A1 (es)
CR (1) CR20150084A (es)
EA (1) EA027176B1 (es)
ES (1) ES2590531T3 (es)
HK (1) HK1206721A1 (es)
IL (1) IL237266A0 (es)
MA (1) MA37943B1 (es)
MX (1) MX2015003330A (es)
PE (1) PE20150943A1 (es)
PH (1) PH12015500400A1 (es)
SG (1) SG11201501923WA (es)
TW (1) TWI490213B (es)
WO (1) WO2014040969A1 (es)
ZA (1) ZA201501262B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370661B (es) * 2013-06-19 2019-12-19 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona.
RU2697512C2 (ru) 2014-05-22 2019-08-15 Ф. Хоффманн-Ля Рош Аг Производные индолин-2-она и 1,3-дигидро-пирроло[3,2-c]пиридин-2-она
MY186124A (en) 2014-06-26 2021-06-23 Hoffmann La Roche Indolin-2-one or pyrrolo-pyridin-2-one derivatives
AU2016348493B2 (en) 2015-11-06 2021-02-25 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
CN108137555B (zh) 2015-11-06 2021-02-19 豪夫迈·罗氏有限公司 可用于治疗cns疾病的二氢吲哚-2-酮衍生物
EP3371169B1 (en) 2015-11-06 2019-07-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
WO2017076842A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
CN106065008B (zh) * 2016-06-16 2018-06-05 黑龙江中医药大学 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
WO2023250064A1 (en) * 2022-06-23 2023-12-28 Biogen Ma Inc. Tyrosine kinase 2 inhibitors and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL144822B1 (en) 1984-05-12 1988-07-30 Boehringer Mannheim Gmbh Method of obtaining novel pyrolobenzimidazoles
DE3417643A1 (de) 1984-05-12 1985-11-14 Boehringer Mannheim Gmbh, 6800 Mannheim Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte
DE3445669A1 (de) 1984-12-14 1986-06-19 Boehringer Mannheim Gmbh, 6800 Mannheim Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3501497A1 (de) 1985-01-18 1986-07-24 Boehringer Mannheim Gmbh, 6800 Mannheim Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte
US4835280A (en) 1985-01-18 1989-05-30 Boehringer Mannheim Gmbh Indoline compounds for synthesis of pharmaceutically active pyrrolobenzimidazoles
DE3803775A1 (de) 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
DE3818830A1 (de) 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
DE3925584A1 (de) * 1989-08-02 1991-02-07 Boehringer Mannheim Gmbh Neue n-(dimethyloxophosphinylmethyl-)-lactame, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CA2383623A1 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
AU3770000A (en) 1999-03-24 2000-10-09 Sugen, Inc. Indolinone compounds as kinase inhibitors
PL1632477T3 (pl) * 2003-06-12 2017-07-31 Astellas Pharma Inc. Pochodna benzamidu lub jej sól
CN100562513C (zh) * 2003-06-12 2009-11-25 安斯泰来制药有限公司 苯甲酰胺衍生物或其盐
EP1802579B1 (en) 2004-10-20 2013-11-20 Merck Serono SA Derivatives of 3-arylaminopyridine
US20060142247A1 (en) 2004-12-17 2006-06-29 Guy Georges Tricyclic heterocycles
EP1955697B1 (en) 2005-11-30 2012-05-02 Astellas Pharma Inc. 2-aminobenzamide derivatives as vanilloid receptor 1 (vr1) inhibitors useful for the treatment of pain or bladder function disorder
EP2182935A1 (en) * 2007-08-02 2010-05-12 F. Hoffmann-Roche AG The use of benzamide derivatives for the treatment of cns disorders
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
WO2010123139A1 (ja) * 2009-04-24 2010-10-28 持田製薬株式会社 スルファモイル基を有するアリールカルボキサミド誘導体
CA2816753A1 (en) * 2010-11-08 2012-05-18 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases

Also Published As

Publication number Publication date
EA201590438A1 (ru) 2015-06-30
WO2014040969A1 (en) 2014-03-20
US20150284386A1 (en) 2015-10-08
EA027176B1 (ru) 2017-06-30
CA2883817C (en) 2017-09-05
AU2013314417A1 (en) 2015-03-05
MX2015003330A (es) 2015-06-05
EP2895476A1 (en) 2015-07-22
KR20150054991A (ko) 2015-05-20
PH12015500400A1 (en) 2015-04-27
JP2015529673A (ja) 2015-10-08
JP6116693B2 (ja) 2017-04-19
MA37943A1 (fr) 2016-04-29
ES2590531T3 (es) 2016-11-22
CA2883817A1 (en) 2014-03-20
TW201416358A (zh) 2014-05-01
CN104619701B (zh) 2016-10-19
HK1206721A1 (en) 2016-01-15
SG11201501923WA (en) 2015-04-29
KR101706877B1 (ko) 2017-02-15
ZA201501262B (en) 2016-03-30
TWI490213B (zh) 2015-07-01
CN104619701A (zh) 2015-05-13
PE20150943A1 (es) 2015-06-20
CL2015000559A1 (es) 2015-07-10
CR20150084A (es) 2015-04-06
EP2895476B1 (en) 2016-06-22
US9221816B2 (en) 2015-12-29
BR112015005186A2 (pt) 2017-07-04
MA37943B1 (fr) 2016-11-30
IL237266A0 (en) 2015-04-30
AU2013314417B2 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
AR092555A1 (es) 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc
CO2017011174A2 (es) Derivados de etileno como moduladores metabotropicos de receptores de glutamato
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR105668A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
PE20180233A1 (es) Nuevos compuestos biciclicos como inhibidores duales de atx / ca
PE20181197A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
PE20151446A1 (es) Peptidos como agonistas de oxitocina
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
AR099047A1 (es) Derivados etinilo
PE20141556A1 (es) Derivados de etinilo como moduladores alostericos de mglur5
AR086036A1 (es) DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5)
PE20170427A1 (es) Peptidos como agonistas de la oxitocina
AR097721A1 (es) Derivados de etinilo
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
MX2016008536A (es) Derivados de fluoro-naftilo.
AR105662A1 (es) Derivados de piridina y de pirimidina como inhibidores del eaat3
UY35393A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CR20130476A (es) Derivados de pirazolidin-3-ona
AR073794A1 (es) Derivados heterociclicos de triazinas sustituidas, medicamentos que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento del alzheimer y otro tipo de demencias.
AR103952A1 (es) Derivados de pirimidina-diona
CR20160563A (es) Péptidos como agonistas de la oxitocina
AR107490A1 (es) Derivados de pirazol-piridina como inhibidores de eaat3
AR072200A1 (es) Derivados dibenzotiazepina y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure